GemVax Publishes Phase 2 Clinical Trial Results of Alzheimer's Disease in SCI-Level International Journal

[Asia Economy Reporter Hyunseok Yoo] GemVax & Kael announced on the 29th that a paper on the Alzheimer's disease treatment GV1001 was published online on the 26th in the SCI-level international journal Alzheimer's Research & Therapy.

Alzheimer's Research & Therapy is recognized as a globally prestigious international journal ranked in the top 10% in the field of Alzheimer's disease. It is published by BioMed Central (BMC), which provides academic journals and databases in science, technology, and medicine, and publishes research on clinical trials, drug discovery and development, epidemiological studies, as well as basic research related to Alzheimer's disease.

The title of the paper published in Alzheimer's Research & Therapy this time is "Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial," which contains an analysis of the full data from the phase 2 clinical trial for Alzheimer's disease conducted in Korea.

According to the paper, a phase 2 clinical trial evaluating the safety and efficacy of GV1001 was conducted at 12 medical institutions in Korea. The results showed a significant improvement (7.1 points) in the primary endpoint, the Severe Impairment Battery (SIB) score, and statistical significance in the secondary endpoint, the Neuropsychiatric Inventory (NPI). Notably, no clinically significant adverse effects or abnormal reactions were observed in the GV1001 treatment group.

Professor Seongho Ko, a neurologist at Hanyang University College of Medicine and the principal investigator of the clinical trial, said, "We are very pleased that our research has been recognized through a world-renowned journal in the field of Alzheimer's disease research," adding, "As recognition of GV1001's research achievements as an Alzheimer's disease treatment continues both domestically and internationally, interest in upcoming clinical trials will increase not only in Korea but also in the global market."

A GemVax representative stated, "The publication of the clinical trial results of GV1001 in Alzheimer's Research & Therapy, a journal boasting global authority in the field of Alzheimer's disease, is a successful and scientifically meaningful achievement," and added, "We will do our best, hoping for good results in clinical trials for the development of Alzheimer's disease treatments to be conducted both domestically and internationally."

Meanwhile, GemVax recently submitted the phase 3 clinical trial plan (IND) for GV1001 for Alzheimer's disease to the Ministry of Food and Drug Safety and is preparing subsequent procedures. They are also maintaining close consultations with a local CRO to expedite the phase 2 clinical trial in the United States.

This content was produced with the assistance of AI translation services.